Cargando…
Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma
INTRODUCTION: Adult T‐cell leukemia‐lymphoma (ATL) is a mature T‐cell lymphoproliferative neoplasm caused by human T‐cell leukemia virus type‐1 infection. There is no standard treatment for relapsed or refractory (r/r) ATL, and clinical outcomes are poor. This systematic review examined the survival...
Autores principales: | Nosaka, Kisato, Crawford, Bruce, Yi, Jingbo, Kuan, William, Matsumoto, Tomoko, Takahashi, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299810/ https://www.ncbi.nlm.nih.gov/pubmed/34862665 http://dx.doi.org/10.1111/ejh.13728 |
Ejemplares similares
-
Adult T‐cell leukemia‐lymphoma as a viral disease: Subtypes based on viral aspects
por: Nosaka, Kisato, et al.
Publicado: (2021) -
Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019) -
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
por: Izutsu, Koji, et al.
Publicado: (2023) -
Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma
por: Tsutsué, Saaya, et al.
Publicado: (2021) -
Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
por: Izutsu, Koji, et al.
Publicado: (2021)